ClinicalTrials.gg
CompletedNCT07334886Updated Jan 12, 2026

A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)

A Phase 1 interventional study of [14C]Ulonivirine in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The goal of this study is to learn how [14C]ulonivirine moves through a healthy person's body over time. Researchers will study how [14C]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria include but are not limited to:

  • Is in good health
  • Has a (BMI) of 18 to 32 kg/m\^2

Key Exclusion Criteria include but are not limited to:

  • Has a history of cancer
  • Has positive tests for surface antigen, antibodies or antibody
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]Ulonivirine

    All participants receive a single oral dose of \[14C\]ulonivirine on Day 1.

    Drug: [14C]Ulonivirine

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative Percentage of Total Radioactivity Recovered (FE) from Urine and Feces

    Urine and fecal samples will be collected to determine the cumulative percentage of radioactivity recovered from both urine and feces.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  2. FE from Urine

    Urine samples will be collected to determine the percent of total radioactivity recovered from urine.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  3. FE from Feces

    Fecal samples will be collected to determine the percent of total radioactivity recovered from feces.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  4. Cumulative Amount of Radioactivity Recovered from Urine

    Urine samples will be collected to determine the cumulative amount of radioactivity recovered from urine.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  5. Percent of Total Radioactive Dose Recovered from Urine

    Urine samples will be collected to determine the percent of the total radioactive dose recovered from urine.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  6. Cumulative Amount of Radioactivity Recovered from Feces

    Fecal samples will be collected to determine the cumulative amount of radioactivity recovered from feces.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  7. Percent of Total Radioactive Dose Recovered from Feces

    Fecal samples will be collected to determine the percent of the total radioactive dose recovered from feces.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  8. Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Concentration (AUC0-last)

    Plasma samples will be collected to determine the AUC0-last of ulonivirine.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  9. Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf)

    Plasma samples will be collected to determine the AUC0-inf of ulonivirine.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  10. Plasma Ulonivirine: Maximum Observed Concentration (Cmax)

    Plasma samples will be collected to determine the Cmax of ulonivirine.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  11. Plasma Ulonivirine: Concentration at 168 Hours Postdose (C168)

    Plasma samples will be collected to determine the C168 of ulonivirine.

    Time frame: At approximately 1 week postdose

  12. Plasma Ulonivirine: Terminal Half-life (t1/2)

    Plasma samples will be collected to determine the t1/2 of ulonivirine.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  13. Plasma Ulonivirine: Time of Maximum Observed Concentration (Tmax)

    Plasma samples will be collected to determine the Tmax of ulonivirine.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  14. Ratio of Ulonivirine to Total Plasma Radioactivity: AUC0-last (ulonivirine)/ AUC0-last (total radioactivity)

    Plasma samples will be collected to determine the ratio of ulonivirine to total plasma radioactivity: AUC0-last (ulonivirine)/ AUC0-last (total radioactivity)

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  15. Plasma Total Radioactivity: AUC0-last

    Plasma samples will be collected to determine the AUC0-last of total radioactivity.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  16. Plasma Total Radioactivity: AUC0-inf

    Plasma samples will be collected to determine the AUC0-inf of total radioactivity.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  17. Plasma Total Radioactivity: Cmax

    Plasma samples will be collected to determine the Cmax of total radioactivity.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  18. Plasma Total Radioactivity: C168

    Plasma samples will be collected to determine the C168 of total radioactivity.

    Time frame: At approximately 1 week postdose

  19. Plasma Total Radioactivity: t1/2

    Plasma samples will be collected to determine the t1/2 of total radioactivity.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  20. Plasma Total Radioactivity: Tmax

    Plasma samples will be collected to determine the Tmax of total radioactivity.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  21. Total Number of Metabolites in Plasma that Represent at least 10% of the Dose of Radioactivity

    Plasma samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  22. Total Number of Metabolites in Urine that Represent at least 10% of the Dose of Radioactivity

    Urine samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

  23. Total Number of Metabolites in Feces that Represent at least 10% of the Dose of Radioactivity

    Fecal samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.

    Time frame: At designated timepoints (up to approximately 5 weeks postdose)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 5 weeks

  2. Number of Participants Who Discontinue the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 5 weeks

07

Study locations

1 site
  • Fortea CRU Madison (Site 002)
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Nov 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Jan 12, 2026
StartActual
Sep 17, 2025
Primary completionActual
Nov 11, 2025
CompletionActual
Nov 11, 2025
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334886
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Sep 17, 2025
Primary completion
Nov 11, 2025
Completion
Nov 11, 2025
Last update
Jan 12, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ulonivirine

Start the discussion